Sanofi to Acquire Kymab for ~$1.45B

January 11, 2021 Auto Bot Acquire, M&A, Sanofi 0

Shots:

  • Sanofi to acquire Kymab for $1.1B up front and ~$350M following the achievement of certain milestones. The transaction is expected to be completed in H1’21
  • The acquisition will add KY1005 to Sanofi’s pipeline and will expedite its presence in the field of immunology
  • Sanofi will get the global rights of KY1005 which is a mAb targeting OX40-ligand, currently being evaluated in early P-I/II study as monothx. and in combination with an anti-PD-L1 for immune-mediated diseases and inflammatory disorders

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Bloomberg

The post Sanofi to Acquire Kymab for ~$1.45B first appeared on PharmaShots.